NCT02634827View on ClinicalTrials.gov

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 30, 2015

Primary Completion Date

March 18, 2017

Study Completion Date

June 12, 2018

Conditions
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsFLT3 Tyrosine Kinase Domain Point MutationSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Midostaurin

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT02634827 - Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | Biotech Hunter | Biotech Hunter